News
EQRXW
0.1900
-20.83%
-0.0500
BRIEF-EQRx Says Jami Rubin Will Step Down As Chief Financial Officer
Reuters · 03/13 13:42
BRIEF-Eqrx Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Reuters · 02/23 23:11
BRIEF-Eqrx Inc Files Prospectus Relates To Issuance By Co Of Of Up To 19.7 Million Shares Of Common Stock - SEC Filing
Reuters · 02/23 23:11
BRIEF-Softbank Group Corp Is Determined To Sell Some Or All Holdings Of Shares Of EQRX In Open Market
Reuters · 01/18 22:29
BRIEF-EQRx Inc Expects To Report That It Had About $1.4 Bln Of Cash, Cash Equivalents And Short-Term Investments As Of Dec 31, 2022
Reuters · 01/11 13:51
BRIEF-EQRx Reports Q3 Loss Of $0.18 Per Share
Reuters · 11/10/2022 13:34
BRIEF-EQRx reports Q2 results
BRIEF-EQRx reports Q2 results
Reuters · 08/11/2022 11:39
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx’s first regulatory submission (aumolertinib) for review; first sugemalimab regulatory submi...
GlobeNewswire · 08/11/2022 11:00
EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free survival versus placebo in patients with u...
GlobeNewswire · 08/07/2022 08:10
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference...
GlobeNewswire · 07/28/2022 12:00
Companies Like EQRx (NASDAQ:EQRX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 07/03/2022 12:22
EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, 2022 (GLOB...
GlobeNewswire · 06/14/2022 11:00
EQRx to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will parti...
GlobeNewswire · 05/31/2022 12:00
BRIEF-Eqrx Announces New Data For Lead Oncology Programs In Non-Small Cell Lung Cancer And Rare Form Of Non-Hodgkin Lymphoma At Asco 2022
reuters.com · 05/26/2022 23:42
EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV non-small cell lung cancer (NSCLC)In a Phase 2 trial, suge...
GlobeNewswire · 05/26/2022 21:00
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line S...
GlobeNewswire · 05/13/2022 11:00
EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conferenc...
GlobeNewswire · 04/29/2022 12:00
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC)Oral presentation featuring the primary anal...
GlobeNewswire · 04/27/2022 14:30
What Type Of Shareholders Own The Most Number of EQRx, Inc. (NASDAQ:EQRX) Shares?
Every investor in EQRx, Inc. ( NASDAQ:EQRX ) should be aware of the most powerful shareholder groups. Generally...
Simply Wall St. · 03/24/2022 15:39
BRIEF-EQRx Reports Fourth Quarter And Full Year 2021 Financial Results
reuters.com · 03/23/2022 11:12
More
Webull provides a variety of real-time EQRXW stock news. You can receive the latest news about Eqrx Inc through multiple platforms. This information may help you make smarter investment decisions.
About EQRXW
CM Life Sciences III Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target. The Company intends to execute business combination in the life sciences sector.